Ontology highlight
ABSTRACT:
SUBMITTER: Blonde L
PROVIDER: S-EPMC6822975 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature
Blonde Lawrence L Bailey Timothy S TS Chao Jason J Dex Terry A TA Frias Juan Pablo JP Meneghini Luigi F LF Roberts Michelle M Aroda Vanita R VR
Advances in therapy 20190729 9
<h4>Introduction</h4>iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients with type 2 diabetes. This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 ...[more]